Translating immuno-onco-microbiome-based therapeutics: precision bugs for immune checkpoint drugs!

Ann Oncol. 2023 Jun;34(6):503-506. doi: 10.1016/j.annonc.2023.03.002.

Authors

V Subbiah¹, S Pant²

Affiliations

¹ Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: vsubbiah@mdanderson.org.
² Department of GI Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: Spant@mdanderson.org.

PMID: 37295905
DOI: 10.1016/j.annonc.2023.03.002

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy
Microbiota*
Neoplasms* / drug therapy

Grants and funding